FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Sharp Shalini   2. Issuer Name and Ticker or Trading Symbol ANTIGENICS INC /DE/ [AGEN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CFO (Last) (First) (Middle) C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900 3. Date of Earliest Transaction (Month/Day/Year) 07/15/2009 (Street) NEW YORK, NY 10010 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/14/2009   A(1) V 115,200 A (1) 205,291 D   Common Stock 07/15/2009   S(2)   13,271 D $ 1.763 192,020 D   Common Stock 07/16/2009   S(2)   32,525 D $ 1.618 159,495 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option, right to buy

$ 12.45

07/16/2009

J(3)

20,000

(3)

07/16/2009

Common Stock

20,000

$ 12.45

320,267

D

Stock Option, right to buy

$ 10.36

07/16/2009

J(3)

6,800

(3)

07/16/2009

Common Stock

6,800

$ 10.36

313,467

D

Stock Option, right to buy

$ 9.43

07/16/2009

J(3)

20,000

(3)

07/16/2009

Common Stock

20,000

$ 9.43

293,467

D

Stock Option, right to buy

$ 5.13

07/16/2009

J(3)

20,000

(3)

07/16/2009

Common Stock

20,000

$ 5.13

273,467

D

Stock Option, right to buy

$ 1.58

07/16/2009

A

50,100

10/16/2009(4)

07/16/2019

Common Stock

50,100

$ 1.58

323,567

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Sharp Shalini C/O ANTIGENICS INC. 162 FIFTH AVE., SUITE 900 NEW YORK, NY 10010			CFO

Signatures

Christine M. Klaskin, by Power of Attorney		07/17/2009
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Represents settlement of restricted stock which was granted on January 14, 2009 in lieu of an annual cash bonus for 2008 performance.
(2)	Represents exclusively, shares sold to cover minimum federal, state, and local tax withholding requirements upon the vesting of the restricted shares granted in lieu of a cash bonus for 2008 performance.
(3)	Options cancelled pursuant to terms of the offer by Antigenics Inc. to exchange certain outstanding options granted under the Antigenics 1999 Equity Incentive Plan, as amended for options to be granted under the 2009 Equity Incentive Plan.
(4)	Options vest in 6 equal quarterly installments over an 18 month period beginning October 16, 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.